Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia (ARMY)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02353143|
Recruitment Status : Active, not recruiting
First Posted : February 2, 2015
Last Update Posted : August 9, 2018
|Condition or disease||Intervention/treatment||Phase|
|Recurrent Adult Acute Myeloid Leukemia Acute Myeloid Leukemia, in Relapse||Drug: MEN1112||Phase 1|
This trial is designed as an open label, non randomised, dose escalation and cohort expansion, first administration to human study to be conducted in approximately 20 European sites. The study is aiming to identify the Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD), to assess the pharmacokinetics and to determine the clinical activity and potential immunogenicity of MEN1112, administered as IV infusion given once every week in a 21 days cycle in patients with relapsed/refractory acute myeloid leukemia (AML).
Approximately 50 male and female ≥ 18 years-old patients, with a documented diagnosis of relapsed or refractory AML (not M3 FAB subtype), will be treated in the study, which consists of two steps.
Step 1 is the dose escalation phase according to a 3+3 patients cohort design.Incremental mg/Kg doses will be tested given at day 1, 8 and 15 of a 21-day cycle. Briefly, MEN1112 doses are to be administered to 3 patients; if no DLT is observed in a cohort of 3 DLT evaluable patients at a given dose level, the next cohort of 3 new patients will be treated with the next higher dose. In case of DLT occurrence by one of the three patients at any dose, the cohort will be expanded to 6 DLT evaluable patients at the same dose level. If two or more patients at a given dose level exhibit DLT, the dose escalation phase will be concluded as the MTD will be identified as one dose level below the one at which ≥ 2 DLT out of 6 treated patients occur.
Step 2 is the cohort expansion phase which will include patients treated at the MTD or the maximum dose level judged to be tolerable.
In each study Step, patients will be given two induction cycles of MEN1112 followed by a three weeks End of Induction period. Patients will then undergo to 4 post-induction/maintenance visits every 28 days (maintenance administration is allowed in patients who achieve a clinical benefit based on Investigator's judgement) and to an End of Study Visit. Along the study period, adverse events, changes in hematology/serum biochemistry parameters and bone marrow treatment response will represent the major clinical findings to be monitored on regular basis. The individual experimental clinical phase will last up to 6 months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration) encompassing 40 planned visits at site, including Screening, Induction, End of Induction, Post-induction/Maintenance and the End of Study visit.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||First in Man Study With MEN1112, a CD157 Targeted Monoclonal Antibody, in Relapsed or Refractory Acute Myeloid Leukemia.|
|Study Start Date :||December 2014|
|Estimated Primary Completion Date :||January 2019|
|Estimated Study Completion Date :||December 2019|
Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation
Intravenous infusion of MEN1112 pro/Kg body weight dose on days 1, 8, 15 of a 21-day cycle. Two induction cycles followed by a 3 week End of induction period. Post-induction/Maintenance Visits every 4 weeks with or without maintenance treatment administration, whilst clinical benefit is maintained as per Investigator's judgement. The individual treatment/observation period is six months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration).
- Dose limiting toxicity (DLT) [ Time Frame: over 3 weeks after the first dose ]
DLT is defined as an adverse event occurring within the first induction cycle, judged to be related to MEN1112 and meeting any of the following criteria:
- Grade 3 non- haematological toxicity lasting more than 7 days.
- Grade ≥ 4 non- haematological toxicity
- Maximum tolerated dose (MTD) [ Time Frame: over 3 weeks after the first dose ]MTD is defined as one dose level below the Maximum Administered Dose (i.e. one dose level below the one at which ≥ 2 DLTs out of 6 treated patients occur).
- Treatment Emergent Signs and Symptoms (TESSs) [ Time Frame: 6 months ]Incidence, severity, seriousness and treatment-causality of Treatment Emergent Signs and Symptoms (TESSs)
- MEN1112 Pharmacokinetic (PK) parameter AUC0-∞ [ Time Frame: Estimated maximum time frame: 4 weeks ]AUC0-∞ is the area under the serum concentration-time curve from time zero extrapolated to infinite time.
- MEN1112 PK parameter Cmax [ Time Frame: Estimated maximum time frame: 4 weeks ]Cmax is the maximum serum drug concentration
- MEN1112 PK parameter t1/2 [ Time Frame: Estimated maximum time frame: 4 weeks ]t1/2 is the drug elimination half-life
- Complete remission (CR) rate [ Time Frame: 6 months ]CR rate at any time point, where CR is defined as: bone marrow blasts <5%, absence of extramedullary disease, absolute neutrophil count >1 x 109/L and platelet count > 100 x 109/L
- Best response rate [ Time Frame: 6 months ]best observed response at any time point between CR, CRi [where CRi is defined as: all criteria for CR except residual thrombocytopenia (platelets <100 x 109/L) and/or neutropenia (absolute neutrophil count <1 x 109/L)] and partial remission [(PR): all haematological criteria for CR with bone marrow blasts 5-25% and decrease of pre-treatment bone marrow blast percentage by at least 50%].
- Overall survival [ Time Frame: 6 months ]number of days between the first study drug administration and death from any cause
- Immunogenicity of MEN1112 [ Time Frame: 64 days ]Incidence of anti-MEN1112 auto-antibodies
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02353143
|Antwerp, Belgium, 2060|
|Bruxelles, Belgium, 1200|
|Liège, Belgium, 4000|
|Yvoir, Belgium, 5530|
|Lille, France, 59037|
|Marseille, France, 13273|
|Nantes, France, 44093|
|Toulouse, France, 31059|
|Villejuif, France, 94805|
|Essen, Germany, 45147|
|Frankfurt, Germany, 60590|
|Munich, Germany, 81377|
|Bologna, Italy, 40126|
|Brescia, Italy, 25123|
|Milano, Italy, 20132|
|Rome, Italy, 00133|
|Torino, Italy, 10126|
|Badalona, Spain, 08916|
|Barcelona, Spain, 08035|
|Valencia, Spain, 46026|
|Study Chair:||Adriano Venditti, Professor, MD||Hematology Department, "Tor Vergata" University Viale Oxford, 81 00133 Rome, Italy|